Chairperson's Remarks
Christian Klein, PhD, Head, Oncology Programs and Department Head, Cancer Immunotherapy Discovery, Roche Innovation Center Zurich, Roche Pharma Research & Early Development, pRED
Immunotherapy Highlights
Taruna Arora, PhD, Vice President, Biotherapeutics, Bristol Myers Squibb
Multispecific Antibody Highlights
Tomoyuki Igawa, PhD, Vice President, Discovery Research Division, Chugai Pharmaceutical Co.,Ltd
ADC Highlights
Hironori Matsunaga, PhD, Scientist, Discovery Research Lab I Group II, Daiichi Sankyo Co., Ltd.
Considerations for the Successful Development of Targeted Radiotherapies
Urs B. Hagemann, PhD, Head, Targeted Radiopharmaceuticals, Research & Early Development Oncology, Bayer AG
Design and Engineering of TCR-Based Immune Cell Engagers for Solid Tumour Indications
Rodrigo Vazquez-Lombardi, PhD, Co-Founder & CSO, Engimmune Therapeutics AG
Aplitabart, an Anti-DR-5 IgM Antibody for Treatment of Colorectal Carcinoma
Bruce Keyt, PhD, CSO, R&D, IGM Biosciences, Inc.
Computational Design of Membrane Protein Structures, Functions, and Therapeutics
Patrick Barth, PhD, Associate Professor, Protein and Cell Engineering, EPFL
Understanding, Predicting, and Mitigating Toxicities with ADCs and Bispecifics
Elisa Fontana, MD, PhD, Oncologist and Medical Director, Sarah Cannon Research Institute UK
Fireside Chat: The Science and Business of Bispecific Antibodies
Moderator:
Janine Schuurman, PhD, Biotech Consultant, Lust for Life Science B.V.
Panelists:
Bassil I. Dahiyat, PhD, CEO, Xencor Inc.
Ton Logtenberg, PhD, Former CEO & Executive Director, Merus NV
Broadly-Reactive Antibody against Multiple Gluten Peptide, HLA-DQ2.5 Complexes for the Treatment of Celiac Disease
Tomoyuki Igawa, PhD, Vice President, Discovery Research Division, Chugai Pharmaceutical Co.,Ltd
The Present and Future of Bispecific Antibodies for Cancer Therapy
Christian Klein, PhD, Head, Oncology Programs and Department Head, Cancer Immunotherapy Discovery, Roche Innovation Center Zurich, Roche Pharma Research & Early Development, pRED
Uncovering the Role of Non-Coding Genome: A Revolution in Cancer Therapeutics and Human Health
Laszlo G. Radvanyi, PhD, President & Scientific Director, Ontario Institute for Cancer Research
HLA-Agnostic T Cell Receptor Recognition of Cancer
Andrew Sewell, PhD, Distinguished Research Professor and Wellcome Trust Senior Investigator, Division of Infection and Immunity, Cardiff University School of Medicine
Moving the Dial on Computational Antibody Design—Optimising beyond Affinity
Charlotte M. Deane, PhD, Professor, Structural Bioinformatics, Statistics, University of Oxford; Executive Chair, Engineering and Physical Sciences Research Council (EPSRC)
Microheterogeneity Assessment of Biopharmaceuticals Using an Orbitrap Tribrid Mass Spectrometer
Jonathan Bones, PhD, Principal Investigator, Characterisation and Comparability Laboratory, National Institute for Bioprocessing Research and Training (NIBRT), Ireland
Role of Aggregation in Therapeutic Antibodies Immunogenicity: Initiation of Innate and Specific Immune Responses
Isabelle Turbica, PhD, Associate Professor, Biotechnology, School of Pharmacy, Paris-Saclay University, France
Target 2035: The Goal to Develop a Pharmacological Modulator for Every Human Protein
Nicola Burgess-Brown, PhD, COO and Consultant, Protein Sciences, Structural Genomics Consortium; Visiting Scientist, University College London
Optimisation Step 1—Choosing a Suitable Gene Expression System for Your Recombinant Protein Production
Nick Berrow, PhD, Manager, Protein Expression Core Facility, Institute for Research in Biomedicine IRB Barcelona, Barcelona Institute of Science and Technology (BIST)
Novel Dual-Payload ADCs That Show Excellent Biophysical Properties and High Efficacy in Vivo
Philipp Spycher, PhD, CEO, Araris Biotech AG
* As of 17 July. Please see individual agenda pages for most up-to-date agenda.